Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / ADSs
-
Shares outstanding
-
592,878
-
Number of holders
-
17
-
Total 13F shares, excl. options
-
283,618
-
Shares change
-
+61,922
-
Total reported value, excl. options
-
$1,077,000
-
Value change
-
+$263,027
-
Number of buys
-
8
-
Number of sells
-
-4
-
Price
-
$3.79
Significant Holders of Scinai Immunotherapeutics Ltd. - ADSs (BVXV) as of Q1 2021
18 filings reported holding BVXV - Scinai Immunotherapeutics Ltd. - ADSs as of Q1 2021.
Scinai Immunotherapeutics Ltd. - ADSs (BVXV) has 17 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 283,618 shares
of 592,878 outstanding shares and own 48% of the company stock.
Largest 10 shareholders include STATE STREET CORP (77,911 shares), MORGAN STANLEY (41,521 shares), HRT FINANCIAL LP (31,961 shares), CITADEL ADVISORS LLC (29,300 shares), GOLDMAN SACHS GROUP INC (26,998 shares), Virtu Financial LLC (18,328 shares), GEODE CAPITAL MANAGEMENT, LLC (13,768 shares), TRUE Private Wealth Advisors (12,000 shares), TWO SIGMA ADVISERS, LP (11,100 shares), and ARK Investment Management LLC (9,778 shares).
This table shows the top 17 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.